Biosimilar use in clinical practice is determined by oncologists’ perceptions of and willingness to prescribe them. The authors investigated US oncologists’ perceptions and use of biosimilars.
Stephanie Fortier, PhD
Advertisement
Articles by Stephanie Fortier, PhD
Advertisement
Latest Updated Articles
Oncologists’ Perceptions and Utilization of US Therapeutic Oncology BiosimilarsPublished: December 8th 2022 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Newly Unveiled ACA Premiums Show 26% Average Increase Before Subsidy Expiration
2
Boosting RSV Vaccination in Older Adults Could Save Thousands
3
FDA Guidance to Remove One of the Largest Barriers to Biosimilar Development
4
Real-World Data Key to Optimizing CAR T-Cell Therapy Delivery, Outcomes
5
